Acurx Pharmaceuticals (ACXP US): Synthetic Expert Call Transcript (11 Sep 2026)
Ibezapolstat's clinical value proposition hinges on a "single-agent" paradigm shift: By achieving a 96% clinical cure rate while actively...
92 Views
IPO Databook: Acurx Pharmaceuticals (ACXP US) - Sep 2026
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat...
99 Views
Primer: Acurx Pharmaceuticals (ACXP US) - Aug 2026
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics, with its lead candidate,...
91 Views
No more insights